These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 34801778)

  • 1. European regulatory aspects of phage therapy: magistral phage preparations.
    Verbeken G; Pirnay JP
    Curr Opin Virol; 2022 Feb; 52():24-29. PubMed ID: 34801778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Magistral Phage Preparations: Is This the Model for Everyone?
    Pirnay JP; Verbeken G
    Clin Infect Dis; 2023 Nov; 77(Suppl 5):S360-S369. PubMed ID: 37932120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality and safety requirements for sustainable phage therapy products.
    Pirnay JP; Blasdel BG; Bretaudeau L; Buckling A; Chanishvili N; Clark JR; Corte-Real S; Debarbieux L; Dublanchet A; De Vos D; Gabard J; Garcia M; Goderdzishvili M; Górski A; Hardcastle J; Huys I; Kutter E; Lavigne R; Merabishvili M; Olchawa E; Parikka KJ; Patey O; Pouilot F; Resch G; Rohde C; Scheres J; Skurnik M; Vaneechoutte M; Van Parys L; Verbeken G; Zizi M; Van den Eede G
    Pharm Res; 2015 Jul; 32(7):2173-9. PubMed ID: 25585954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bacteriophages as Therapeutic and Prophylactic Means: Summary of the Soviet and Post Soviet Experiences.
    Chanishvili N
    Curr Drug Deliv; 2016; 13(3):309-23. PubMed ID: 27090515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Medicinal Phage-Regulatory Roadmap for Phage Therapy under EU Pharmaceutical Legislation.
    Faltus T
    Viruses; 2024 Mar; 16(3):. PubMed ID: 38543808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bacteriophage therapy as an alternative treatment for human infections. A comprehensive review.
    Kakasis A; Panitsa G
    Int J Antimicrob Agents; 2019 Jan; 53(1):16-21. PubMed ID: 30236954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stability of magistral phage preparations before therapeutic application in patients with chronic rhinosinusitis, sepsis, pulmonary, and musculoskeletal infections.
    Uyttebroek S; Bessems L; Metsemakers W-J; Debaveye Y; Van Gerven L; Dupont L; Depypere M; Wagemans J; Lavigne R; Merabishvili M; Pirnay J-P; Devolder D; Spriet I; Onsea J
    Microbiol Spectr; 2023 Dec; 11(6):e0290723. PubMed ID: 37819122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bacteriophage therapy: an overview and the position of Italian Society of Infectious and Tropical Diseases.
    Cesta N; Di Luca M; Corbellino M; Tavio M; Galli M; Andreoni M
    Infez Med; 2020 Sep; 28(3):322-331. PubMed ID: 32920567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phage Therapy: The Pharmacology of Antibacterial Viruses.
    Danis-Wlodarczyk K; Dąbrowska K; Abedon ST
    Curr Issues Mol Biol; 2021; 40():81-164. PubMed ID: 32503951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Magistral Phage.
    Pirnay JP; Verbeken G; Ceyssens PJ; Huys I; De Vos D; Ameloot C; Fauconnier A
    Viruses; 2018 Feb; 10(2):. PubMed ID: 29415431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Phage therapy, an additional strategy against multidrug-resistant bacteria].
    Boniver M; Wotquenne P; Moutschen M; Rousseau AF
    Rev Med Liege; 2022 Sep; 77(9):510-515. PubMed ID: 36082597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ameliorating the antimicrobial resistance crisis: phage therapy.
    Saha D; Mukherjee R
    IUBMB Life; 2019 Jul; 71(7):781-790. PubMed ID: 30674079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Call for a dedicated European legal framework for bacteriophage therapy.
    Verbeken G; Pirnay JP; Lavigne R; Jennes S; De Vos D; Casteels M; Huys I
    Arch Immunol Ther Exp (Warsz); 2014 Apr; 62(2):117-29. PubMed ID: 24500660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fighting Pathogenic Bacteria on Two Fronts: Phages and Antibiotics as Combined Strategy.
    Tagliaferri TL; Jansen M; Horz HP
    Front Cell Infect Microbiol; 2019; 9():22. PubMed ID: 30834237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Engineering therapeutic phages for enhanced antibacterial efficacy.
    Meile S; Du J; Dunne M; Kilcher S; Loessner MJ
    Curr Opin Virol; 2022 Feb; 52():182-191. PubMed ID: 34952266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phage Therapy in the Twenty-First Century: Facing the Decline of the Antibiotic Era; Is It Finally Time for the Age of the Phage?
    Hesse S; Adhya S
    Annu Rev Microbiol; 2019 Sep; 73():155-174. PubMed ID: 31185183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Preclinical and Clinical Progress of Bacteriophages and Their Lytic Enzymes: The Parts are Easier than the Whole.
    Abdelkader K; Gerstmans H; Saafan A; Dishisha T; Briers Y
    Viruses; 2019 Jan; 11(2):. PubMed ID: 30678377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bacteriophages: A Therapy Concept against Multi-Drug-Resistant Bacteria.
    Rohde C; Wittmann J; Kutter E
    Surg Infect (Larchmt); 2018; 19(8):737-744. PubMed ID: 30256176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phage Therapy for Antibiotic-Resistant Bacterial Infections.
    Hatfull GF; Dedrick RM; Schooley RT
    Annu Rev Med; 2022 Jan; 73():197-211. PubMed ID: 34428079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Wake-Up Call: We Need Phage Therapy Now.
    Moelling K; Broecker F; Willy C
    Viruses; 2018 Dec; 10(12):. PubMed ID: 30563034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.